# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jackie Robinson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML037-SYN-TD
- Date: 1971-08-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marcus Delacroix-Hale, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Four weeks after the new medicines: potassium and creatinine, blood pressure, ankle-brachial index, feet, mood, and the second eye injections. **S**

## History of present illness

Mr. Robinson returns four weeks after the lisinopril increase and empagliflozin, from his second eye injections this morning. Dr. Ostrowski-Lane reports the blood in the right eye is thinning and the macular swelling is less in both eyes. His heel blister is smaller with the dressings and the offloading shoe, and the podiatrist has seen him twice. Chest tightness is less since cardiology started metoprolol, and he has not used nitroglycerin. He has had no dizziness, genital itching or low blood sugar; fasting readings are 140 to 180 mg/dL. He has met the health center's grief counselor once and plans to continue. **S**

| Element | Detail |
|---|---|
| Eyes | Second injections today; hemorrhage thinning; less swelling |
| Heel | Smaller; podiatry twice |
| Chest | Less tightness on metoprolol |
| Glucose | Fasting 140 to 180 mg/dL; no lows |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Eyes | Positive | Vision a little clearer |
| Cardiovascular | Positive | Calf pain after about a block; chest tightness less |
| Genitourinary | Negative | No burning or genital itching |
| Integumentary | Positive | Heel wound healing |
| Psychiatric | Positive | Grieving; meeting a counselor |

5 systems reviewed. **S**

## Current medications

- Metformin 1,000 mg oral tablet, one tablet twice daily with meals **S**
- Insulin glargine 100 units/mL pen, 30 units at bedtime, adjusted by the written plan: 2 units each week while fasting glucose is above 160 mg/dL, and 4 units less for any reading below 70 **S**
- Atorvastatin 80 mg oral tablet, one tablet daily (increased from 40 mg at intake) **S**
- Aspirin 81 mg delayed-release oral tablet, one tablet daily **S**
- Glucagon 3 mg nasal powder, one spray into the nose for severe low blood sugar; may repeat once after 15 minutes **S**
- Metoprolol succinate extended-release 25 mg oral tablet, one tablet daily **S**
- Nitroglycerin 0.4 mg sublingual tablet, one under the tongue for chest pain, repeated every five minutes up to three; call 911 if pain is not better five minutes after the first **S**
- Lisinopril 40 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating **S**
- Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating, and before surgery or a colonoscopy preparation **S**

## Allergies

- No known allergy **S**

## Objective

BP 134/80 mmHg; pulse 60 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 102.8 kg; BMI 31.7 kg/m². All vital signs are synthetic.

Sodium: 138 mmol/L; Potassium: 4.8 mmol/L; Creatinine: 1.22 mg/dL; eGFR (CKD-EPI 1966, race-free): 71 mL/min/1.73 m² (low); Ankle-brachial index, right: 0.68 (low); Ankle-brachial index, left: 0.74 (low). All results are synthetic.

## Change since baseline

- Sodium: 137 mmol/L at baseline, 138 mmol/L at this visit **S**
- Potassium: 4.6 mmol/L at baseline, 4.8 mmol/L at this visit **S**
- Creatinine: 1.12 mg/dL at baseline, 1.22 mg/dL at this visit **S**
- eGFR (CKD-EPI 1966, race-free): 79 mL/min/1.73 m² (low) at baseline, 71 mL/min/1.73 m² (low) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 134/80, pulse 60; weight 102.8 kg |
| Right foot | Heel wound 1.2 by 1 cm, clean granulating base, no infection |
| Feet | Monofilament absent in both forefeet, as at intake; pulses faint |
| Vascular | Ankle-brachial index 0.68 right and 0.74 left |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Diabetic kidney disease with albuminuria** (E11.22). Potassium 4.8 mmol/L; creatinine 1.22 mg/dL, eGFR 71 from 79: a fall of about 10%, the expected effect of empagliflozin and the higher lisinopril dose. **S**
   - Continue both.
   - Urine albumin and kidney function at three months.
2. **Peripheral artery disease** (E11.51). Ankle-brachial index 0.68 and 0.74: moderate disease in both legs, with claudication at one block. The heel wound is healing, so no vascular procedure is needed now. **S**
   - Supervised exercise therapy three times a week once the heel has healed.
   - Continue statin, aspirin and podiatry.
3. **Hypertension with chronic kidney disease** (I12.9). 134/80, nearly at goal on lisinopril 40 mg and metoprolol. **S**
   - No change.
4. **Bereavement** (Z63.4). Grieving; counseling started; no thoughts of self-harm. **S**
   - Continue counseling; PHQ-9 at three months.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (seated, two readings, large cuff) | Every visit | Completed today | 134/80 |
| Examination | Weight and BMI | Every visit | Completed today | 102.8 kg |
| Laboratory | Potassium, creatinine and eGFR | Two to four weeks after starting or increasing an ACE inhibitor or SGLT2 inhibitor; then every 6 to 12 months | Completed today | Four weeks after the changes: sodium 138, potassium 4.8 mmol/L; creatinine 1.22 mg/dL; eGFR 71 |
| Imaging | Ankle-brachial index | At diagnosis of peripheral artery disease; then with any change in symptoms or a wound | Completed today | 0.68 right and 0.74 left |
| Examination | Foot inspection; comprehensive foot examination | Every visit with loss of sensation; comprehensive examination yearly | Completed today | Heel wound healing; no new breaks; sensation absent as before |
| Imaging | Retina care: acuity, OCT, injections and laser | Monthly at the retina clinic while treating | Completed today | Second injections today; hemorrhage thinning; less swelling (retina clinic report) |
| Laboratory | Hemoglobin A1c | Every 3 months while not at goal or after a change | Up to date | Next at three months |
| Self-management | Glucose log and low blood sugar review (talking meter) | Every visit | Completed today | Fasting 140 to 180 mg/dL on the talking meter; no lows |
| Laboratory | Lipid panel | 4 to 12 weeks after starting or changing a statin; then yearly | Due | Due by twelve weeks after the atorvastatin increase |
| Examination | Angina review | Every visit | Completed today | Less tightness on metoprolol; no nitroglycerin used |
| Medication safety | Medicine safety: low blood sugar, sick-day rules, genital infection, dizziness, cost | Every visit | Completed today | No low blood sugar, dizziness or genital infection |
| Self-management | Low-vision services and diabetes tools he can use | When vision limits daily life | Completed today | Low-vision evaluation booked; talking meter in use; large-print plans |

## Goal progress

- Vision kept or improved: proliferative disease regressed and macular edema reduced on anti-VEGF injections and laser. In progress; target 1971-10-26. **S**
- A1c falling by about one point every three months without low blood sugar, to below 8% within six months and then below 7%. In progress; target 1971-10-26. **S**
- Blood pressure below 130/80 mmHg. In progress; target 1971-10-26. **S**
- LDL cholesterol below 55 mg/dL. In progress; target 1971-10-26. **S**
- Walk at least three blocks without stopping, through supervised exercise. In progress; target 1971-10-26. **S**
- Feet kept intact: daily foot checks he can do with low vision, protective footwear, and prompt care for any skin break. In progress; target 1971-10-26. **S**
- Grief acknowledged and supported, with depression screening repeated. In progress; target 1971-10-26. **S**

## Guideline basis

- 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- Diabetic Retinopathy Preferred Practice Pattern (2025), American Academy of Ophthalmology (Ophthalmology 2025; Lim JI, et al.)
- 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024), American College of Cardiology and American Heart Association (Circulation 2024)
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology (Circulation 2023)
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney International)
- CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, ischemic heart disease, chronic kidney disease and depression monographs (2026), Aether Forge
- Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) (2023), International Working Group on the Diabetic Foot (Diabetes Metab Res Rev 2024)

## Follow-up

- Preventive visit in four weeks. Third injections in four weeks and laser to the right eye when the blood clears. Three-month review in two months with the A1c, urine albumin, lipids and kidney function. **S**
- Next scheduled visit 1971-09-21: periodic adult preventive visit. **S**
